What Is Glow?
Glow is a combined peptide protocol that includes a pen of GHK-Cu and a pen containing BPC-157 & TB-500. This combination is commonly discussed for its potential focus on skin quality, tissue repair, and overall recovery support.
Glow is not a hormone therapy or weight-loss medication. Instead, it brings together peptides studied for cellular signaling, regeneration pathways, and connective tissue support.
How Does Glow Work?
Glow combines peptides with complementary roles:
- GHK-Cu — A copper-binding peptide studied for collagen signaling, skin health, and tissue renewal pathways.
- BPC-157 — Support of tendon, ligament, and gut-related repair signaling.
- TB-500 — A thymosin beta-4 fragment studied for cell migration, flexibility, and recovery-related processes.
By combining these peptides, the Glow protocol focuses on skin appearance, recovery, and regenerative signaling rather than appetite or metabolic hormone pathways.
Potential Benefits?
- Support for skin quality and collagen signaling
- Tissue repair and recovery
- Support for hair and scalp health
- Mobility and soft-tissue recovery support
- Anti-inflammatory signaling observed in some studies
Side Effects and Safety Considerations?
Reported effects may include:
- Injection-site irritation or redness
- Temporary fatigue or headache
- Skin sensitivity or flushing
- Mild nausea in some individuals
Recommended Usage Information?
Estimated half-life:
- GHK-Cu — Short-acting, active for hours rather than days
- BPC-157 — Short-acting peptide studied with more frequent administration
- TB-500 — Longer tissue activity compared to BPC-157
Why it matters:
Glow does not behave like long-acting weekly metabolic medications.
Effects are linked to cellular signaling rather than long-term drug accumulation.
Consistency is typically emphasized over rapid dose escalation.
Steady state concepts used for weekly hormone-based therapies do not apply in the same way to Glow peptides, as these compounds are generally shorter-acting and focused on signaling pathways.
The recommended starting dose for GHK-Cu is 2mg, and for BPC-157 & TB-500, 1mg would be an ideal starting dose.
Gradual adjustments are preferred rather than large increases. If you are experiencing desired results without significant negative side effects, maintaining a consistent approach may be more appropriate than continually increasing.
Our GHK-Cu pen has an adjustable dosage of 2–6mg.
Our BPC-157 & TB-500 pen has an adjustable dosage of 1–4mg.
Both pens have a shelf life of 12–18 months.